Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959140 · ClinicalTrials.gov registry record · NA
Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors
A NA study of Hematopoietic Stem Cell Transplantation, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00959140 is a NA study of Hematopoietic Stem Cell Transplantation that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00959140, a NA study of Hematopoietic Stem Cell Transplantation, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Stem cells collected from sibling donors for allogenic transplants contain various types of cells. The predominant immune cells are called CD3+ T cells. The amount of these T cells vary vastly from donor to donor. This study is to determine if standardizing the CD3+ T cell dose will benefit the recipient (patient). As well as to help discover if dose standardization causes less variation in outcomes between patients and to make transplantation more predictable and complications easier to manage.
Conditions Studied
Interventions
- DEVICE CD3+ T cell depletion
Study Locations (1)
Alabama
- University of Alabama Hospital - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-10 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00959140
The ClinicalTrials.gov registry entry for NCT00959140 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which CD3+ T cell depletion is the first listed.
NCT00959140 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00959140 about?
NCT00959140 is a clinical study titled "Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors". Stem cells collected from sibling donors for allogenic transplants contain various types of cells. The predominant immune cells are called CD3+ T cells. The amount of these T cells vary vastly from donor to donor. This study is to determine if standardizing the CD3+ T cell dose will benefit the reci...
What is the current status of trial NCT00959140?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2014-10. Estimated completion is 2026-12-31.
What conditions does trial NCT00959140 study?
This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplantation.
What interventions are being tested in trial NCT00959140?
The interventions under investigation include: CD3+ T cell depletion (DEVICE).
Who is sponsoring clinical trial NCT00959140?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00959140 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Employment Support After Hematopoietic Stem Cell Transplantation
RECRUITING · NA
-
Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States
RECRUITING · NA
-
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
RECRUITING · NA
-
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
RECRUITING · NA
-
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
RECRUITING · NA
-
Art and Physical Therapy in Pediatric HCT
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.